Selected research
Industry Research
Antihemorrhagic Agent Industry Research Report 2026
Market perspective
The global Antihemorrhagic Agent market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Antihemorrhagic Agent is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Antihemorrhagic Agent is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Antihemorrhagic Agent is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Antihemorrhagic Agent include Biocer, C. R. Bard (BD), Celox, Equimedical, Ethicon, Gelita Medical, Hemostasis, Hemotec Medical and MBP, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Antihemorrhagic Agent market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Antihemorrhagic Agent Market by Company
Biocer
C. R. Bard (BD)
Celox
Equimedical
Ethicon
Gelita Medical
Hemostasis
Hemotec Medical
MBP
Medira
Starch Medical
Pfizer
Success Pharmaceutical
Changsha Hairun
Antihemorrhagic Agent Segment by Type
Microfibrillar Collagen
Chitosan
Other
Antihemorrhagic Agent Segment by Application
Surgical Wound Care
General Wound Care
Antihemorrhagic Agent Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antihemorrhagic Agent market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Antihemorrhagic Agent and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antihemorrhagic Agent.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Antihemorrhagic Agent manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Antihemorrhagic Agent by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Antihemorrhagic Agent in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Microfibrillar Collagen
- Chitosan
- Other
Applications
- Surgical Wound Care
- General Wound Care
Companies covered
- Biocer
- C. R. Bard (BD)
- Celox
- Equimedical
- Ethicon
- Gelita Medical
- Hemostasis
- Hemotec Medical
- MBP
- Medira
- Starch Medical
- Pfizer
- Success Pharmaceutical
- Changsha Hairun
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Antihemorrhagic Agent Market Size (2021-2032)
- 2.2.2 Global Antihemorrhagic Agent Sales (2021-2032)
- 2.2.3 Global Antihemorrhagic Agent Market Average Price (2021-2032)
- 2.3 Antihemorrhagic Agent by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Microfibrillar Collagen
- 2.3.3 Chitosan
- 2.3.4 Other
- 2.4 Antihemorrhagic Agent by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Surgical Wound Care
- 2.4.3 General Wound Care
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Antihemorrhagic Agent Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Antihemorrhagic Agent Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Antihemorrhagic Agent Revenue of Manufacturers (2021-2026)
- 3.4 Global Antihemorrhagic Agent Average Price by Manufacturers (2021-2026)
- 3.5 Global Antihemorrhagic Agent Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Antihemorrhagic Agent, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Antihemorrhagic Agent, Product Type & Application
- 3.8 Global Manufacturers of Antihemorrhagic Agent, Established Date
- 3.9 Global Antihemorrhagic Agent Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Biocer
- 4.1.1 Biocer Company Information
- 4.1.2 Biocer Business Overview
- 4.1.3 Biocer Antihemorrhagic Agent Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Biocer Antihemorrhagic Agent Product Portfolio
- 4.1.5 Biocer Recent Developments
- 4.2 C. R. Bard (BD)
- 4.2.1 C. R. Bard (BD) Company Information
- 4.2.2 C. R. Bard (BD) Business Overview
- 4.2.3 C. R. Bard (BD) Antihemorrhagic Agent Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 C. R. Bard (BD) Antihemorrhagic Agent Product Portfolio
- 4.2.5 C. R. Bard (BD) Recent Developments
- 4.3 Celox
- 4.3.1 Celox Company Information
- 4.3.2 Celox Business Overview
- 4.3.3 Celox Antihemorrhagic Agent Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Celox Antihemorrhagic Agent Product Portfolio
- 4.3.5 Celox Recent Developments
- 4.4 Equimedical
- 4.4.1 Equimedical Company Information
- 4.4.2 Equimedical Business Overview
- 4.4.3 Equimedical Antihemorrhagic Agent Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Equimedical Antihemorrhagic Agent Product Portfolio
- 4.4.5 Equimedical Recent Developments
- 4.5 Ethicon
- 4.5.1 Ethicon Company Information
- 4.5.2 Ethicon Business Overview
- 4.5.3 Ethicon Antihemorrhagic Agent Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Ethicon Antihemorrhagic Agent Product Portfolio
- 4.5.5 Ethicon Recent Developments
- 4.6 Gelita Medical
- 4.6.1 Gelita Medical Company Information
- 4.6.2 Gelita Medical Business Overview
- 4.6.3 Gelita Medical Antihemorrhagic Agent Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Gelita Medical Antihemorrhagic Agent Product Portfolio
- 4.6.5 Gelita Medical Recent Developments
- 4.7 Hemostasis
- 4.7.1 Hemostasis Company Information
- 4.7.2 Hemostasis Business Overview
- 4.7.3 Hemostasis Antihemorrhagic Agent Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Hemostasis Antihemorrhagic Agent Product Portfolio
- 4.7.5 Hemostasis Recent Developments
- 4.8 Hemotec Medical
- 4.8.1 Hemotec Medical Company Information
- 4.8.2 Hemotec Medical Business Overview
- 4.8.3 Hemotec Medical Antihemorrhagic Agent Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Hemotec Medical Antihemorrhagic Agent Product Portfolio
- 4.8.5 Hemotec Medical Recent Developments
- 4.9 MBP
- 4.9.1 MBP Company Information
- 4.9.2 MBP Business Overview
- 4.9.3 MBP Antihemorrhagic Agent Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 MBP Antihemorrhagic Agent Product Portfolio
- 4.9.5 MBP Recent Developments
- 4.10 Medira
- 4.10.1 Medira Company Information
- 4.10.2 Medira Business Overview
- 4.10.3 Medira Antihemorrhagic Agent Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Medira Antihemorrhagic Agent Product Portfolio
- 4.10.5 Medira Recent Developments
- 4.11 Starch Medical
- 4.11.1 Starch Medical Company Information
- 4.11.2 Starch Medical Business Overview
- 4.11.3 Starch Medical Antihemorrhagic Agent Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Starch Medical Antihemorrhagic Agent Product Portfolio
- 4.11.5 Starch Medical Recent Developments
- 4.12 Pfizer
- 4.12.1 Pfizer Company Information
- 4.12.2 Pfizer Business Overview
- 4.12.3 Pfizer Antihemorrhagic Agent Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Pfizer Antihemorrhagic Agent Product Portfolio
- 4.12.5 Pfizer Recent Developments
- 4.13 Success Pharmaceutical
- 4.13.1 Success Pharmaceutical Company Information
- 4.13.2 Success Pharmaceutical Business Overview
- 4.13.3 Success Pharmaceutical Antihemorrhagic Agent Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Success Pharmaceutical Antihemorrhagic Agent Product Portfolio
- 4.13.5 Success Pharmaceutical Recent Developments
- 4.14 Changsha Hairun
- 4.14.1 Changsha Hairun Company Information
- 4.14.2 Changsha Hairun Business Overview
- 4.14.3 Changsha Hairun Antihemorrhagic Agent Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Changsha Hairun Antihemorrhagic Agent Product Portfolio
- 4.14.5 Changsha Hairun Recent Developments
5 Global Antihemorrhagic Agent Market Scenario by Region
- 5.1 Global Antihemorrhagic Agent Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Antihemorrhagic Agent Sales by Region: 2021-2032
- 5.2.1 Global Antihemorrhagic Agent Sales by Region: 2021-2026
- 5.2.2 Global Antihemorrhagic Agent Sales by Region: 2027-2032
- 5.3 Global Antihemorrhagic Agent Revenue by Region: 2021-2032
- 5.3.1 Global Antihemorrhagic Agent Revenue by Region: 2021-2026
- 5.3.2 Global Antihemorrhagic Agent Revenue by Region: 2027-2032
- 5.4 North America Antihemorrhagic Agent Market Facts & Figures by Country
- 5.4.1 North America Antihemorrhagic Agent Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Antihemorrhagic Agent Sales by Country (2021-2032)
- 5.4.3 North America Antihemorrhagic Agent Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Antihemorrhagic Agent Market Facts & Figures by Country
- 5.5.1 Europe Antihemorrhagic Agent Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Antihemorrhagic Agent Sales by Country (2021-2032)
- 5.5.3 Europe Antihemorrhagic Agent Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Antihemorrhagic Agent Market Facts & Figures by Country
- 5.6.1 Asia Pacific Antihemorrhagic Agent Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Antihemorrhagic Agent Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Antihemorrhagic Agent Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Antihemorrhagic Agent Market Facts & Figures by Country
- 5.7.1 South America Antihemorrhagic Agent Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Antihemorrhagic Agent Sales by Country (2021-2032)
- 5.7.3 South America Antihemorrhagic Agent Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.7.7 Colombia
- 5.8 Middle East and Africa Antihemorrhagic Agent Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Antihemorrhagic Agent Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Antihemorrhagic Agent Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Antihemorrhagic Agent Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Antihemorrhagic Agent Sales by Type (2021-2032)
- 6.1.1 Global Antihemorrhagic Agent Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Antihemorrhagic Agent Sales Market Share by Type (2021-2032)
- 6.2 Global Antihemorrhagic Agent Revenue by Type (2021-2032)
- 6.2.1 Global Antihemorrhagic Agent Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Antihemorrhagic Agent Revenue Market Share by Type (2021-2032)
- 6.3 Global Antihemorrhagic Agent Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Antihemorrhagic Agent Sales by Application (2021-2032)
- 7.1.1 Global Antihemorrhagic Agent Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Antihemorrhagic Agent Sales Market Share by Application (2021-2032)
- 7.2 Global Antihemorrhagic Agent Revenue by Application (2021-2032)
- 7.2.1 Global Antihemorrhagic Agent Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Antihemorrhagic Agent Revenue Market Share by Application (2021-2032)
- 7.3 Global Antihemorrhagic Agent Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Antihemorrhagic Agent Value Chain Analysis
- 8.1.1 Antihemorrhagic Agent Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Antihemorrhagic Agent Production Mode & Process
- 8.2 Antihemorrhagic Agent Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Antihemorrhagic Agent Distributors
- 8.2.3 Antihemorrhagic Agent Customers
9 Global Antihemorrhagic Agent Analyzing Market Dynamics
- 9.1 Antihemorrhagic Agent Industry Trends
- 9.2 Antihemorrhagic Agent Industry Drivers
- 9.3 Antihemorrhagic Agent Industry Opportunities and Challenges
- 9.4 Antihemorrhagic Agent Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst